Meningioma | NET | ||||||||
Quantity | Organ | Parameter | Minimum | Maximum | Median | Minimum | Maximum | Median | Literature |
Receptor concentration | Kidneys | RK,0 (nmol·L−1) | 5.7 | 8.8 | 6.5 | 2.3 | 8.7 | 7.1 | 9 ± 8* |
Spleen | RS,0 (nmol·L−1) | 7.8 | 16.5 | 9.2 | 3.9 | 18 | 8.7 | 30 ± 26* | |
Liver | RL,0 (nmol·L−1) | 0.86 | 2.5 | 1.1 | 0.63 | 2.1 | 1.2 | 2 ± 1* | |
Rest | RREST,0 (nmol·L−1) | 0.39 | 0.94 | 0.53 | 0.48 | 0.48 | 0.48 | — | |
Tumor | RTU,0 (nmol·L−1) | 5.0 | 34 | 17 | 7 | 35 | 16 | 34*; 8–80† | |
Release rate | Normal tissue | λNT,release (min−1·10−4) | 0.47 | 1.7 | 0.65 | 0.60 | 2.3 | 1.2 | 1.2–1.6‡; 0.5–1.6* |
Tumor | λTU,release (min−1·10−4) | 1.1 | 3.0 | 1.7 | 0 | 2.1 | 0 | 1.2–1.6‡; 0.4–3.0* | |
Volume | Tumor rest¶ | VTU,Total,Rest (L) | 0 | 1.2 | 0.10 | — | |||
Perfusion | Tumor | fTU, (mL·min−1 ·g−1) | 0.10 | 1.0 | 0.20 | 0.015 | 1.0 | 0.064 | 0.01–1§ |
Linear binding rate | Serum protein | kPr (min−1·10−4) | 2.1 | 5.6 | 4.3 | 10 | 23 | 17 | — |
↵* Data from Kletting et al. (9) obtained using pharmacokinetic model with simpler structure; 111In-Octreoscan (dissociation constant = 5.57 nmol/L) data and smaller amounts (5.8 ± 0.4 nmol) of peptide were used.
↵† Calculations based on 80 fmol·10−6 cells (34) and assumption of 1011 or 1012 cells L−1 tumor.
↵‡ Derived from half-life (3–4 d) for release of rates of 111In (35).
↵¶ Volume of nondelineated, remaining tumor tissue § (36).